Browse the evidence

No significant associations were found between white rice intake and risk of cardiovascular diseases, CVD mortality, cancer, and metabolic syndrome.

Practitioners can inform patients that white rice does not appear to significantly impact these other health risks.

Long-term cardiovascular outcome data for recent anti-obesity medications remain inconclusive or lacking.

Practitioners should be cautious and consider the lack of long-term data when prescribing these medications.

Moorehead-Ardelt scores were higher in the bypass group at 2 years but showed no statistically significant differences later on.

Practitioners should note that while bypass may improve certain quality of life metrics initially, this effect may not persist long-term.

Obesity is a global epidemic and a chronic, progressive disease.

Recognizing obesity as a chronic disease can influence treatment approaches.

Tirzepatide has a half-life of five days, allowing for once-weekly administration.

Practitioners can schedule tirzepatide administration once a week due to its five-day half-life.

No competitor characteristic predicted any of the resistance training variables manipulated during peak week.

Competitors may not need to tailor their training adjustments based on individual characteristics during peak week.

There is a significant multiplicative interaction of cardiovascular autonomic neuropathy (CAN) and sex on both mortality outcomes.

Understanding the interaction between CAN and sex can improve risk assessment and management strategies in diabetes care.

Most adverse events (AEs) associated with incretin-based therapies (IBTs) are mild or moderate and mainly occur during dose escalation.

Clinicians should monitor patients for mild to moderate AEs, especially during dose increases.

Only 2 out of 41 studies (approximately 5%) reported or assessed dietary intake or evaluated diet changes secondary to GLP-1/GIP RA medication use.

Practitioners should be aware of the lack of dietary assessment in studies involving GLP-1/GIP medications.

The quality of dietary assessment methods used in the studies was categorized as 'poor' and 'acceptable'.

Practitioners should consider the quality of dietary assessment methods when interpreting study results.

The review highlights a major gap in the evidence requiring urgent attention for high-quality research on dietary impacts of GLP-1/GIP medications.

There is a critical need for more rigorous studies to assess dietary changes associated with these medications.

Patients identified three risks associated with obesity treatment.

Understanding these risks can help healthcare providers address patient concerns and improve treatment uptake.

The uptake of obesity treatments remains disproportionally low in people living with the disease.

Healthcare providers should be aware of the low uptake to better engage patients in treatment options.

Consensus recommendations for safe practices in bariatric and metabolic surgery tourism (BMT) were established by healthcare professionals and patient representatives across Europe.

Healthcare providers should adhere to the established consensus recommendations for BMT.

Further evaluation is required regarding outcomes following bariatric and metabolic surgery tourism.

Ongoing research is essential to assess the effectiveness and safety of BMT practices.

The intervention subjects lost more weight than the control subjects (-4.1 kg vs -2.1 kg), but the difference was not statistically significant (p = 0.22).

Practitioners may consider remote dietitian support for weight loss in patients before joint surgery.

The intervention subjects had higher odds of achieving a BMI of <40 kg/m 2 (odds ratio = 1.9), but this was not statistically significant (p = 0.44).

Practitioners may find that remote interventions can help some patients achieve a healthier BMI before surgery.

Obesity is a chronic multifactorial disease.

Understanding obesity as a multifactorial disease is crucial for effective treatment.

There has been limited success in curbing the incidence of T2D despite lifestyle modification being standard care.

Practitioners should recognize the barriers to effective lifestyle interventions.

The incidence of type 2 diabetes among non-operated patients with obesity was 11.7% during the follow-up period.

Non-operated obese patients have a high incidence of type 2 diabetes, highlighting the need for effective interventions.

The incidence of type 2 diabetes among gastric bypass patients was comparable to that of the general population.

Gastric bypass surgery can reduce diabetes risk to levels similar to those in the general population, indicating its effectiveness.

PA may not be a critical factor influencing weight maintenance in PWD.

Weight maintenance strategies for PWD may need to consider factors beyond just physical activity.

Habitual sleep duration did not alter overfeeding-mediated body weight gain, fat gain, and fat distribution.

Sleep duration may not influence weight or fat gain during overfeeding.

The evidence supporting GLP-1RAs for treating PsO and PsA remains limited.

Further clinical research is needed to establish the efficacy and safety of GLP-1RAs for PsO and PsA.